<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/analysts-anticipate-bristol-myers-squibb-co-nysebmy-will-announce-earnings-of-0-89-per-share.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T18:34:45+00:00"/>
    <meta property="og:title" content="Analysts Anticipate Bristol-Myers Squibb Co (NYSE:BMY) Will Announce Earnings of $0.89 Per Share"/>
    <meta property="og:description" content="Equities research analysts expect Bristol-Myers Squibb Co (NYSE:BMY) to announce earnings of $0.89 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Bristol-Myers Squibb’s earnings. The lowest EPS estimate is $0.87 and the highest is $0.90. Bristol-Myers Squibb posted earnings of $0.94 per share during the same […]"/>
  </head>
  <body>
    <article>
      <h1>Analysts Anticipate Bristol-Myers Squibb Co (NYSE:BMY) Will Announce Earnings of $0.89 Per Share</h1>
      <address><time datetime="2019-11-24T18:34:45+00:00">24 Nov 2019, 18:34</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/bristol-myers-squibb-co-logo.jpg"/>
      </figure>
      <p>Equities research analysts expect Bristol-Myers Squibb Co (NYSE:BMY) to announce earnings of $0.89 per share for the current quarter, according to <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a>. Two analysts have made estimates for Bristol-Myers Squibb’s earnings. The lowest EPS estimate is $0.87 and the highest is $0.90. Bristol-Myers Squibb posted earnings of $0.94 per share during the same quarter last year, which would indicate a negative year over year growth rate of 5.3%. The company is scheduled to issue its next quarterly earnings report on Thursday, January 23rd.</p>
      <p>On average, analysts expect that Bristol-Myers Squibb will report full-year earnings of $4.38 per share for the current fiscal year, with EPS estimates ranging from $4.28 to $4.62. For the next year, analysts forecast that the business will report earnings of $5.27 per share, with EPS estimates ranging from $4.44 to $6.04. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Bristol-Myers Squibb.</p>
      <p>Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.11. The firm had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company earned $1.09 EPS.</p>
      <p>A number of research analysts have commented on the company. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, November 18th. Wolfe Research set a $66.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, November 1st. UBS Group increased their price objective on Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Wednesday, October 23rd. Peel Hunt reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, October 29th. Finally, TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $57.95.</p>
      <p>In other news, SVP John E. Elicker sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now directly owns 74,471 shares in the company, valued at approximately $4,219,526.86. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through <a href="https://www.sec.gov/Archives/edgar/data/14272/000001427219000197/xslF345X03/wf-form4_157307724710649.xml">the SEC website</a>. Also, insider Louis S. Schmukler sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/14272/000001427219000198/xslF345X03/wf-form4_157307726808681.xml">here</a>. 0.13% of the stock is owned by company insiders.</p>
      <p>Institutional investors have recently modified their holdings of the stock. Lodestar Investment Counsel LLC IL raised its stake in Bristol-Myers Squibb by 5.2% during the 2nd quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock worth $5,157,000 after buying an additional 5,579 shares during the period. Cypress Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 21.2% in the 2nd quarter. Cypress Capital Management LLC now owns 154,335 shares of the biopharmaceutical company’s stock valued at $6,999,000 after purchasing an additional 26,990 shares during the period. Nachman Norwood &amp; Parrott Inc raised its stake in shares of Bristol-Myers Squibb by 3.5% in the 2nd quarter. Nachman Norwood &amp; Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock valued at $2,285,000 after purchasing an additional 1,687 shares during the period. Edge Wealth Management LLC raised its stake in shares of Bristol-Myers Squibb by 217.7% in the 2nd quarter. Edge Wealth Management LLC now owns 10,007 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 6,857 shares during the period. Finally, KG&amp;L Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 38.6% in the 2nd quarter. KG&amp;L Capital Management LLC now owns 17,104 shares of the biopharmaceutical company’s stock valued at $775,000 after purchasing an additional 4,761 shares during the period. 82.87% of the stock is currently owned by institutional investors and hedge funds.</p>
      <p><a href="https://www.marketbeat.com/stocks/NYSE/BMY/earnings/">BMY</a> traded down $0.40 during mid-day trading on Friday, reaching $56.45. The stock had a trading volume of 21,515,626 shares, compared to its average volume of 24,056,136. The stock has a market capitalization of $92.62 billion, a P/E ratio of 14.18, a P/E/G ratio of 1.32 and a beta of 0.71. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. The firm’s fifty day simple moving average is $54.83 and its two-hundred day simple moving average is $48.95. Bristol-Myers Squibb has a 52 week low of $42.48 and a 52 week high of $59.17.</p>
      <p>The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were given a $0.41 dividend. The ex-dividend date was Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 2.91%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.</p>
      <p>
        <b>Bristol-Myers Squibb Company Profile</b>
      </p>
      <p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/what-is-an-inverted-yield-curve/">What causes a yield curve to invert?</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=BMY">Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/>
      </figure>
    </article>
  </body>
</html>